Similarly, systemic lupus erythematosus (SLE), multiple sclerosis (MS), interstitial lung disease (ILD), and inflammatory bowel disease (IBD) have been exacerbated in patients treated with PD-1/PD-L1 inhibitors [47,48,49,50]. Here, PDCD1 is linked to inflammatory bowel disease.